Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC1 Pipeline in Oncology
Proceeds from the financing will support the advancement of three first- and best-in-class ADC programs through upcoming key clinical milestones While oncology continues to face substantial and largely unmet needs, Jeito will leverage its expertise to accelerate Adcendo’s broad, high-potential portfolio of novel therapies and deliver transformational benefits to patients PARIS — Jeito Capital (“Jeito”), […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.